Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 1 of 1 entries
Sorted by: Best Match Show Resources per page
Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes.

PharmacoEconomics

Geng J, Yu H, Mao Y, Zhang P, Chen Y.
PMID: 25736235
Pharmacoeconomics. 2015 Jun;33(6):581-97. doi: 10.1007/s40273-015-0266-y.

BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of antidiabetic drugs used for treating type 2 diabetes mellitus. While many studies have reported on the cost-effectiveness of DPP-4 inhibitors for treating type 2 diabetes, a systematic review of...

Cite
Geng J, Yu H, Mao Y, et al. Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Pharmacoeconomics. 2015;33(6):581-97doi: 10.1007/s40273-015-0266-y.
Geng, J., Yu, H., Mao, Y., Zhang, P., & Chen, Y. (2015). Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes. PharmacoEconomics, 33(6), 581-97. https://doi.org/10.1007/s40273-015-0266-y
Geng, Jinsong, et al. "Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes." PharmacoEconomics vol. 33,6 (2015): 581-97. doi: https://doi.org/10.1007/s40273-015-0266-y
Geng J, Yu H, Mao Y, Zhang P, Chen Y. Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Pharmacoeconomics. 2015 Jun;33(6):581-97. doi: 10.1007/s40273-015-0266-y. PMID: 25736235.
Copy Download .nbib Format: NLM
Showing 1 to 1 of 1 entries